PALI Key Statistics, Chart & Performance
The current stock price of PALI is 1.525 USD. In the past month the price decreased by -17.71%. In the past year, price increased by 26.4%.
PALI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PALI. When comparing the yearly performance of all stocks, PALI turns out to be only a medium performer in the overall market: it outperformed 67.29% of all stocks.
PALI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PALI. While PALI has a great health rating, there are worries on its profitability.
PALI Financial Highlights
Over the last trailing twelve months PALI reported a non-GAAP Earnings per Share(EPS) of -2.98. The EPS increased by 82.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.7% | ||
| ROE | -192.71% | ||
| Debt/Equity | 0 |
PALI Forecast & Estimates
10 analysts have analysed PALI and the average price target is 13.43 USD. This implies a price increase of 780.66% is expected in the next year compared to the current price of 1.525.
PALI Ownership
PALI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.89 | 383.716B | ||
| AMGN | AMGEN INC | 16.4 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.73 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.55 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.04 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PALI
Company Profile
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 8 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Company Info
PALISADE BIO INC
7750 El Camino Real, Suite 5200
Carlsbad CALIFORNIA 20876 US
CEO: Kenneth Carter
Employees: 8
Phone: 18587044900
PALISADE BIO INC / PALI FAQ
What does PALISADE BIO INC do?
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 8 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Can you provide the latest stock price for PALISADE BIO INC?
The current stock price of PALI is 1.525 USD. The price decreased by -3.48% in the last trading session.
Does PALISADE BIO INC pay dividends?
PALI does not pay a dividend.
How is the ChartMill rating for PALISADE BIO INC?
PALI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for PALI stock?
PALISADE BIO INC (PALI) currently has 8 employees.
What is PALISADE BIO INC worth?
PALISADE BIO INC (PALI) has a market capitalization of 227.22M USD. This makes PALI a Micro Cap stock.
What is the outstanding short interest for PALISADE BIO INC?
The outstanding short interest for PALISADE BIO INC (PALI) is 12.78% of its float.